肠道菌群在肝细胞癌中的作用及治疗应用的研究进展

doi:10.11904/j.issn.1002-3070.2023.03.015

Abstract

Abstract: Hepatocellular carcinoma(HCC)is one of the tumors with high morbidity and mortality in the world.Due to the close and special relationship between intestine and liver,gut microbiota can affect chronic liver disease and promote the occurrence and development of HCC through the interaction between intestine and liver.This article mainly introduces that gut microbiota promotes the occurrence and development of HCC through intestinal leakage and MAMPs Toll like receptors,imbalance of flora and its metabolites,and regulation of tumor microenvironment.Targeting gut microbiota,such as antibiotics to kill harmful flora,antagonists inhibiting TLR,probiotic imbalance of flora and FMT to improve gut microbiota,provides a new strategy for the treatment of HCC.

Key words: Hepatocellular carcinoma, Gut microbiota, Chronic liver disease, Tumor therapy

YIN Dingwei, JING Jie. Research progress on the role of Gut microbiota in hepatocellular carcinoma and its therapeutic application[J]. Journal of Practical Oncology, 2023, 37(3): 281-286.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/10.11904/j.issn.1002-3070.2023.03.015

http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/Y2023/V37/I3/281

References

1 Sung H,Ferlay J,Siegel RL,et al.Global Cancer Statistics 2020 GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2021,71(3):209-249.
2 Vitiello GA,Cohen DJ,Miller G.Harnessing the microbiome for pancreatic cancer immunotherapy[J].Trends Cancer,2019,5(11):670-676.
3 Garrett WS.Cancer and the microbiota[J].Science,2015,348(6230):80-86.
4 Whisner CM,Athena Aktipis C.The role of the microbiome in cancer initiation and progression:how microbes and cancer cells utilize excess energy and promote one another′s growth[J].Current Nutrition Reports,2019,8(1):42-51.
5 Aykut B,Pushalkar S,Chen R,et al.The fungal mycobiome promotes pancreatic oncogenesis via activation of MBL[J].Nature,2019,574(7777):264-267.
6 Bonnet M,Buc E,Sauvanet P,et al.Colonization of the human gut by E.coli and colorectal cancer risk[J].Clin Cancer Res,2014,20(4):859-867.
7 Tripathi A,Debelius J,Brenner DA,et al.The gut-liver axis and the intersection with the microbiome[J].Nat Rev Gastroenterol Hepatol,2018,15(7):397-411.
8 Sender R,Fuchs S,Milo R.Are we really vastly outnumbered? Revisiting the ratio of bacterial to host cells in humans[J].Cell,2016,164(3):337-340.
9 Flint HJ.Gut microbial metabolites in health and disease[J].Gut Microbes,2016,7(3):187-188.
10 Martinez KB,Leone V,Chang EB.Microbial metabolites in health and disease:navigating the unknown in search of function[J].J Biol Chem,2017,292(21):8553-8559.
11 Chu H,Duan Y,Yang L,et al.Small metabolites,possible big changes:a microbiota-centered view of non-alcoholic fatty liver disease[J].Gut,2019,68(2):359-370.
12 Wood S,Pithadia R,Rehman T,et al.Chronic alcohol exposure renders epithelial cells vulnerable to bacterial infection[J].PLoS One,2013,8(1):54646.
13 Chen P,Stärkel P,Turner JR,et al.Dysbiosis-induced intestinal inflammation activates tumor necrosis factor receptor I and mediates alcoholic liver disease in mice[J].Hepatology,2015,61(3):883-894.
14 Rohr MW,Narasimhulu CA,Rudeski-Rohr TA,et al.Negative effects of a high-fat diet on intestinal permeability:a review[J].Adv Nutr,2020,11(1):77-91.
15 Stenman LK,Holma R,Korpela R.High-fat-induced intestinal permeability dysfunction associated with altered fecal bile acids[J].World J Gastroenterol,2012,18(9):923-929.
16 阿比丹·拜合提亚尔郭津生.慢性肝病病因特异与非特异的肝细胞肝癌发生机制[J].泸州医学院学报,2021,44(6):593-600.
17 Lu H,Wu Z,Xu W,et al.Intestinal microbiota was assessed in cirrhotic patients with hepatitis B virus infection.Intestinal microbiota of HBV cirrhotic patients[J].Microb Ecol,2011,61(3):693-703.
18 Mutlu EA,Gillevet PM,Rangwala H,et al.Colonic microbiome is altered in alcoholism[J].Am J Physiol Gastrointest Liver Physiol,2012,302(9):966-978.
19 Said I,Ahad H,Said A.Gut microbiome in non-alcoholic fatty liver disease associated hepatocellular carcinoma:current knowledge and potential for therapeutics[J].World J Gastrointest Oncol,2022,14(5):947-958.
20 Albillos A,De Gottardi A,Rescigno M.The gut-liver axis in liver disease:pathophysiological basis for therapy[J].J Hepatol,2020,72(3):558-577.
21 Sandahl TD,Gronbaek H,Moller H J,et al.Hepatic macrophage activation and the LPS pathway in patients with alcoholic hepatitis:a prospective cohort study[J].Am J Gastroenterol,2014,109(11):1749-1756.
22 Petrasek J,Mandrekar P,Szabo GJGR, et al.Toll-like receptors in the pathogenesis of alcoholic liver disease[J].Gastroenterol Res Pract,2010,2010(12).
23 Hoyles L,Fernandez-Real JM,Federici M,et al.Molecular phenomics and metagenomics of hepatic steatosis in non-diabetic obese women[J].Nat Med,2018,24(7):1070-1080.
24 Abenavoli L,Scarpellini E,Colica C,et al.Gut microbiota and obesity:a role for probiotics[J].Nutrients,2019,11(11):2690.
25 Jiang C,Xie C,Li F,et al.Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease[J].J Clin Invest,2015,125(1):386.
26 Roderburg C,Luedde T.The role of the gut microbiome in the development and progression of liver cirrhosis and hepatocellular carcinoma[J].Gut Microbes,2014,5(4):441-445.
27 Yoshimoto S,Loo TM,Atarashi K,et al.Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome[J].Nature,2013,499(7456):97-101.
28 Yu LX,Yan HX,Liu Q,et al.Endotoxin accumulation prevents carcinogen-induced apoptosis and promotes liver tumorigenesis in rodents[J].Hepatology,2010,52(4):1322-1333.
29 Dapito DH,Mencin A,Gwak GY,et al.Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4[J].Cancer Cell,2012,21(4):504-516.
30 Schnabl B,Brenner DA.Interactions between the intestinal microbiome and liver diseases[J].Gastroenterology,2014,146(6):1513-1524.
31 Bajaj JS,Heuman DM,Hylemon PB,et al.Altered profile of human gut microbiome is associated with cirrhosis and its complications[J].J Hepatol,2014,60(5):940-947.
32 Lv LX,Fang DQ,Shi D,et al.Alterations and correlations of the gut microbiome,metabolism and immunity in patients with primary biliary cirrhosis[J].Environ Microbiol,2016,18(7):2272-2286.
33 De Minicis S,Rychlicki C,Agostinelli L,et al.Dysbiosis contributes to fibrogenesis in the course of chronic liver injury in mice[J].Hepatology,2014,59(5):1738-1749.
34 Yamada S,Takashina Y,Watanabe M,et al.Bile acid metabolism regulated by the gut microbiota promotes non-alcoholic steatohepatitis-associated hepatocellular carcinoma in mice[J].Oncotarget,2018,9(11):9925-9939.
35 Lee WJ,Hase K.Gut microbiota-generated metabolites in animal health and disease[J].Nat Chem Biol,2014,10(6):416-424.
36 Ma C,Han M,Heinrich B,et al.Gut microbiome-mediated bile acid metabolism regulates liver cancer via NKT cells[J].Science,2018,eaan5931.
37 Li Q,Ma L,Shen S,et al.Intestinal dysbacteriosis-induced IL-25 promotes development of HCC via alternative activation of macrophages in tumor microenvironment[J].J Exp Clin Cancer Res,2019,38(1):303.
38 刘熙称,童曼曼,李凌巍,等.肠道菌群与肝细胞癌关系的研究进展[J].胃肠病学和肝病学杂志,2021,30(1):42-46.
39 Gangarapu V,Ince AT,Baysal B,et al.Efficacy of rifaximin on circulating endotoxins and cytokines in patients with nonalcoholic fatty liver disease[J].Eur J Gastroenterol Hepatol,2015,27(7):840-845.
40 Yu LX,Schwabe RF.The gut microbiome and liver cancer:mechanisms and clinical translation[J].Nat Rev Gastroenterol Hepatol,2017,14(9):527-539.
41 Hill C,Guarner F,Reid G,et al.Expert consensus document.The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic[J].Nat Rev Gastroenterol Hepatol,2014,11(8):506-514.
42 Li J,Sung CY,Lee N,et al.Probiotics modulated gut microbiota suppresses hepatocellular carcinoma growth in mice[J].Proc Natl Acad Sci U S A,2016,113(9):1306-1315.
43 Zhang HL,Yu LX,Yang W,et al.Profound impact of gut homeostasis on chemically-induced pro-tumorigenic inflammation and hepatocarcinogenesis in rats[J].J Hepatol,2012,57(4):803-812.
44 Elshaer AM,El-Kharashi OA,Hamam GG,et al.Involvement of TLR4/CXCL9/PREX-2 pathway in the development of hepatocellular carcinoma(HCC)and the promising role of early administration of lactobacillus plantarum in Wistar rats[J].Tissue Cell,2019,60:38-47.
45 Kang Y,Cai Y.Gut microbiota and hepatitis-B-virus-induced chronic liver disease:implications for faecal microbiota transplantation therapy[J].J Hosp Infect,2017,96(4):342-348.
46 Van Nood E,Vrieze A,Nieuwdorp M,et al.Duodenal infusion of donor feces for recurrent Clostridium difficile[J].N Engl J Med,2013,368(5):407-415.
47 Khoruts A,Rank KM,Newman KM,et al.Inflammatory bowel disease affects the outcome of fecal microbiota transplantation for recurrent clostridium difficile infection[J].Clin Gastroenterol Hepatol,2016,14(10):1433-1438.
48 Kang Y,Pan W,Cai Y.Gut microbiota and colorectal cancer:insights into pathogenesis for novel therapeutic strategies[J].Z Gastroenterol,2017,55(9):872-880.
49 Kang YB,Cai Y.Faecal microbiota transplantation enhances efficacy of immune checkpoint inhibitors therapy against cancer[J].World J Gastroenterol,2021,27(32):5362-5375.

[1]	CUI Yongkang, YU Chengping, XU Haozhi, MA Xinyu, MA Yong, LI Linqiang. Effects of nutritional risk index in predicting postoperative complications and prognosis of patients with resectable hepatocellular carcinoma [J]. Journal of Practical Oncology, 2023, 37(3): 243-251.
[2]	WANG Jiabei, ZHANG Yunguang, LIU Lianxin. Clinical efficacy and safety analysis of immunotherapy combined with molecularly targeted drugs in the treatment of advanced hepatocellular carcinoma:A single-arm retrospective study [J]. Journal of Practical Oncology, 2022, 36(6): 489-494.
[3]	CHEN Yali, LIU Ting, CHEN Juan, DU Qiujing. Research progress on the relationship between perioperative intestinal flora and neuropsychiatric symptoms in cancer patients [J]. Journal of Practical Oncology, 2022, 36(5): 468-471.
[4]	LIU Jia, YANG Daokun, WANG Yanping, CHEN Baoxin, WANG Xinwei, SHEN Jiao. Research status of biomarkers related to the efficacy of PD-1 inhibitors in the treatment of hepatocellular carcinoma [J]. Journal of Practical Oncology, 2022, 36(4): 374-380.
[5]	LIU Jiaming, CUI Yifeng, LU Zhaoyang. Aqueous Huaier extract inhibits the proliferation and metastasis of hepatocellular carcinoma by regulating the Akt signaling pathway through mitochondrial transcription factor A [J]. Journal of Practical Oncology, 2022, 36(3): 203-207.
[6]	PANG Chunhua, LI Fanrong, TANG Rubing, QIN Lei, ZHAO Xinhua, TANG Juan, YOU Xuemei. Association between preoperative fatigue status and postoperative quality of life in patients with advanced hepatocellular carcinoma:a prospective cohort study [J]. Journal of Practical Oncology, 2022, 36(2): 127-132.
[7]	LIU Yu, YU Xingxin, GENG Zhida, CHEN Zhengliang, HUI Peng, LIANG Yingjian. The role of liver fibroblasts in the occurrence and development of hepatocellular carcinoma [J]. Journal of Practical Oncology, 2022, 36(2): 167-172.
[8]	WANG Zongwen, LI Xiaodong, ZHU Qiankun, ZENG Shicong, ZHAI Bo. KIF14 in the mechanism of acquired drug resistance in hepatocellular carcinoma SMCC-7721 cells [J]. Journal of Practical Oncology, 2022, 36(1): 14-19.
[9]	LIU Fei, SUI Hong. Research progress in molecular classification of liver cancer based on tumor immunological microenvironment [J]. Journal of Practical Oncology, 2021, 35(6): 557-561.
[10]	JI Lei, JI Daolin, BAO Dongdong, TAN Gang. The latest research progress of long non-coding RNA in sorafenib resistance of hepatocellular carcinoma [J]. Journal of Practical Oncology, 2021, 35(6): 562-567.
[11]	ZHAO Haoran, LI Man, ZHANG Yubao. Research progress of hepatocellular carcinoma-related RNA binding protein [J]. Journal of Practical Oncology, 2021, 35(6): 576-579.
[12]	HE Ling, YAO Kecheng. Glycosylphosphatidylinositol transamidase and hepatocellular carcinoma [J]. Journal of Practical Oncology, 2021, 35(5): 458-461.
[13]	ZHOU Jian,CHEN Xuejian,WANG Wei,LI Ning,SUN Zhenyu,XU Lishan. The effect of silencing PRMT5 gene in biological behavior of human hepatocellular carcinoma cells [J]. Journal of Practical Oncology, 2020, 34(3): 208-213.
[14]	ZHANG Congyi, CUI Yifeng, LI Baobao, LIU Lianxin. Expression of cell division cycle 7 protein in hepatocellular carcinoma tissues and its effect on proliferation and invasion of hepatocellular carcinoma cells [J]. Journal of Practical Oncology, 2020, 34(2): 150-155.
[15]	CHEN Ziyin, BAI Yanchun, CAO Yangsen, LI Jian, XU Lili, ZHAO Qiushuang, WANG Yang. Dosimetry advantage of respiratory gating in the treatment of hepatocellular carcinoma with large segmentation [J]. Journal of Practical Oncology, 2019, 33(6): 536-539.

Research progress on the role of Gut microbiota in hepatocellular carcinoma and its therapeutic application

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments